51
|
Niu J, Li XM, Wang X, Liang C, Zhang YD, Li HY, Liu FY, Sun H, Xie SQ, Fang D. DKK1 inhibits breast cancer cell migration and invasion through suppression of β-catenin/MMP7 signaling pathway. Cancer Cell Int 2019; 19:168. [PMID: 31285694 PMCID: PMC6591985 DOI: 10.1186/s12935-019-0883-1] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Accepted: 06/11/2019] [Indexed: 12/11/2022] Open
Abstract
Background DKK1 has been reported to act as a tumor suppressor in breast cancer. However, the mechanism of DKK1 inhibits breast cancer migration and invasion was still unclear. Methods Western blot and real time PCR was used to detect the expression of DKK1, β-catenin and MMP7 in breast cancer cells. Wound scratch assay and transwell assay was employed to examine migration and invasion of breast cancer cell. Results DKK1 overexpression dramatically inhibits breast cancer cell migration and invasion. Knockdown of DKK1 promotes migration and invasion of breast cancer cells. DKK1 suppressed breast cancer cell migration and invasion through suppression of β-catenin and MMP7 expression. XAV-939, an inhibitor of β-catenin accumulation could reverse DKK1 silencing-induced MMP7 expression in breast cancer cells. Meanwhile, XAV-939 also could reverse the increase in the cell number invaded through Matrigel when DKK1 was knockdown. Furthermore, depletion of MMP7 also could reverse DKK1 knockdown-induced increase in the cell number invaded through Matrigel. Conclusions DKK1 inhibits migration and invasion of breast cancer cell through suppression of β-catenin/MMP7 pathway, our findings offered a potential alternative for breast cancer prevention and treatment.
Collapse
Affiliation(s)
- Jie Niu
- 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China
| | - Xiao-Meng Li
- 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China
| | - Xiao Wang
- 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China
| | - Chao Liang
- 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China
| | - Yi-Dan Zhang
- 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China
| | - Hai-Ying Li
- 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China
| | - Fan-Ye Liu
- 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China
| | - Hua Sun
- 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China
| | - Song-Qiang Xie
- 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China.,2Institute of Chemical Biology, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China
| | - Dong Fang
- 1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, N. Jinming Ave, Kaifeng, 475004 China
| |
Collapse
|
52
|
Lei X, Yang S, Yang Y, Zhang J, Wang Y, Cao M. Long noncoding RNA DLX6-AS1 targets miR-124-3p/CDK4 to accelerate Ewing's sarcoma. Am J Transl Res 2019; 11:6569-6576. [PMID: 31737208 PMCID: PMC6834508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2019] [Accepted: 07/17/2019] [Indexed: 04/15/2023]
Abstract
Ewing's sarcoma is one of leading cause of malignancy occurred in the children and adolescents worldwide. Given the emerging critical role of long noncoding RNA (lncRNA) in the human cancer, as well as Ewing's sarcoma, we aim to identify the biological role of DLX6-AS1 in the tumorigenesis. Results unveil that DLX6-AS1 expression was increased in the tissue sample and cells. Functionally, the silencing of DLX6-AS1 could repress the proliferation and accelerate the apoptosis of Ewing's sarcoma cells. Mechanically, DLX6-AS1 functioned as the sponge of miR-124-3p, and then miR-124-3p targeted the 3'-UTR of CDK4 mRNA, forming the DLX6-AS1/miR-124-3p/CDK4 regulatory pathway. In conclusion, the critical role of DLX6-AS1 might unveil a potential therapeutic target for Ewing's sarcoma.
Collapse
Affiliation(s)
- Xiaomei Lei
- Department of Child Health Care, The Second Affiliated Hospital, Xi’an Jiaotong UniversityXi’an 710004, Shaanxi, China
| | - Siping Yang
- Department of Medical Genetics, Xibei Maternal and Child Health HospitalXi’an 710061, Shaanxi, China
| | - Yuanyuan Yang
- Department of Child Health Care, The Second Affiliated Hospital, Xi’an Jiaotong UniversityXi’an 710004, Shaanxi, China
| | - Juan Zhang
- Department of Neonatal Paediatrics, Xibei Maternal and Child Health HospitalXi’an 710061, Shaanxi, China
| | - Yue Wang
- Department of Child Health Care, The Second Affiliated Hospital, Xi’an Jiaotong UniversityXi’an 710004, Shaanxi, China
| | - Minhui Cao
- Department of Child Health Care, Weinan Maternal and Child Health HospitalWeinan 714000, Shaanxi, China
| |
Collapse
|
53
|
Zhang QH, Hu QX, Xie D, Chang B, Miao HG, Wang YG, Liu DZ, Li XD. Ganoderma lucidum Exerts an Anticancer Effect on Human Osteosarcoma Cells via Suppressing the Wnt/β-Catenin Signaling Pathway. Integr Cancer Ther 2019; 18:1534735419890917. [PMID: 31855073 PMCID: PMC6923688 DOI: 10.1177/1534735419890917] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2019] [Revised: 09/27/2019] [Accepted: 10/22/2019] [Indexed: 02/05/2023] Open
Abstract
Background: Current treatment of osteosarcoma is limited in part by side effects and low tolerability, problems generally avoided with traditional Chinese medicine. Ganoderma lucidum, a traditional Chinese medicine with antitumor effects, offers a potential alternative, but little is known about its molecular mechanisms in osteosarcoma cells. Objective: To investigate the effect of G lucidum on osteosarcoma cells and its mechanism. Methods: Osteosarcoma MG63 and U2-OS cells were treated with G lucidum, followed by assays for cell proliferation (Cell Counting Kit-8), colony formation, and apoptosis (Alexa Fluor 647-Annexin V/propidium iodide, flow cytometry). Migration and invasion of cells were assessed by wound healing and Transwell invasion assays, and the effect of G lucidum on Wnt/β-catenin signal transduction was studied by real-time quantitative polymerase chain reaction, western blot, and dual-luciferase assay. Results:G lucidum inhibited the proliferation, migration, and invasion, and induced apoptosis of human osteosarcoma MG63 and U2-OS cells. Dual-luciferase assay showed that G lucidum suppressed the transcriptional activity of T-cell factor/lymphocyte enhancer factor in the Wnt/β-catenin signaling pathway. Moreover, G lucidum blocked Wnt/β-catenin signaling by inhibiting the Wnt co-receptor LRP5 and Wnt-related target genes, such as β-catenin, cyclin D1, C-Myc, MMP-2, and MMP-9. At the same time, when Wnt/β-catenin was inhibited, the expression of E-cadherin was upregulated. Conclusions: Our results suggest that G lucidum broadly suppresses osteosarcoma cell growth by inhibiting Wnt/β-catenin signaling.
Collapse
Affiliation(s)
- Qi-Hao Zhang
- The First Affiliated Hospital of Shantou
University Medical College, Shantou, Guangdong, People’s Republic of China
| | - Qin-Xiao Hu
- The First Affiliated Hospital of Shantou
University Medical College, Shantou, Guangdong, People’s Republic of China
| | - Da Xie
- The First Affiliated Hospital of Shantou
University Medical College, Shantou, Guangdong, People’s Republic of China
| | - Bo Chang
- The First Affiliated Hospital of Shantou
University Medical College, Shantou, Guangdong, People’s Republic of China
- The Third Affiliated Hospital (The
Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, Guangdong, People’s
Republic of China
| | - Hou-Guang Miao
- The Third Affiliated Hospital (The
Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, Guangdong, People’s
Republic of China
| | - Yun-Guo Wang
- The Second Hospital of Tianjin Medical
University, Tianjin, People’s Republic of China
| | - De-Zhong Liu
- The First Affiliated Hospital of Shantou
University Medical College, Shantou, Guangdong, People’s Republic of China
- De-Zhong Liu, Department of Emergency
Surgery, The First Affiliated Hospital of Shantou University Medical College,
Shantou, Guangdong 515041, People’s Republic of China.
| | - Xue-Dong Li
- The First Affiliated Hospital of Shantou
University Medical College, Shantou, Guangdong, People’s Republic of China
- De-Zhong Liu, Department of Emergency
Surgery, The First Affiliated Hospital of Shantou University Medical College,
Shantou, Guangdong 515041, People’s Republic of China.
| |
Collapse
|